Investview's High-Stakes Pivot: Can Wellness Rescue a Troubled Firm?

HAVERFORD, PA – June 25, 2026 – Investview, Inc. (OTCQB: INVU) subsidiary Conectiv today announced a significant diversification, launching MyLife Wellness, a direct-to-consumer line of supplements and skincare products. The new brand, featuring items like 'Drive' for cognitive function and 'Glow' for skin firming, aims to expand Conectiv's 'lifestyle optimization' platform beyond its traditional focus on financial education tools. “MyLife Wellness combines premium ingredients with modern wellness science to create high-performance formulas designed to support noticeable real-world results,” said Chad Garner, president of Conectiv, in a statement.

However, this foray into the hyper-competitive wellness industry is far from a routine product expansion. It represents a critical, high-stakes maneuver for parent company Investview, which is grappling with plummeting revenues, widening losses, and a stark 'going concern' warning disclosed in its own regulatory filings. The launch of MyLife Wellness is less a story of innovation and more a narrative of corporate survival, betting that a new venture can stabilize a portfolio teetering on the edge.

A Diversification Born of Distress

Beneath the polished marketing of 'vitality stacks' and 'radiance protocols' lies a grim financial reality. Investview's most recent quarterly report paints a bleak picture. For the three months ending March 31, 2026, the company reported a staggering 62.2% year-over-year decrease in gross revenue, which fell to just $4.0 million. Net losses ballooned to $4.1 million for the quarter, a dramatic increase from the $0.9 million loss in the same period a year prior. These figures are not an anomaly but the continuation of a worrying trend, with the company posting an $8.3 million net loss from operations for the full year 2025.

This financial turmoil led the company to include a critical disclosure in its SEC filings: its ability to continue as a 'going concern may be subject to doubt' if its strategic initiatives fail to mitigate losses or if it cannot access additional capital. This warning signals severe liquidity concerns and places immense pressure on any new initiative to deliver immediate results.

The Conectiv segment, the very division launching MyLife Wellness, is a primary source of this financial strain. Its net revenue plunged by 65.2% in the first quarter of 2026 compared to the prior year. This collapse is largely attributed to a December 2025 administrative decision by Poland's Office of Competition and Consumer Protection (UOKiK), which deemed aspects of the company’s direct selling model unlawful and led to an accrual for a potential $3.9 million fine. The ruling crippled Conectiv's European marketing network, a core revenue driver.

Viewed through this lens, the MyLife Wellness launch is a calculated, if desperate, pivot. Investview is attempting to build a new engine for growth while its primary one sputters. The strategy is to diversify away from the troubled financial education sector and into the booming, albeit saturated, health and wellness market, hoping to create a new, more resilient revenue stream.

The Direct Selling Dilemma

The business model for MyLife Wellness hinges on the same direct-selling structure that has brought Investview both success and regulatory trouble. While products are available on a standard e-commerce site, the core strategy involves empowering Conectiv members to sell products at a discount, creating what the company calls 'an additional income stream for themselves within the Conectiv ecosystem.'

This model is central to Investview's turnaround plan. The company's forward-looking statements explicitly state its reliance on 'onboarding certain other direct selling networks' to spur growth. However, these filings also contain a crucial caveat: the new distributors 'are not contractually or otherwise required to sell any Conectiv products or services.' This reveals a strategy dependent on the motivation of an independent, non-obligated sales force, adding a significant layer of uncertainty.

Furthermore, by doubling down on a direct-selling model, Investview is navigating a landscape fraught with regulatory risk. The UOKiK ruling in Poland serves as a stark reminder of the scrutiny that multi-level marketing (MLM) and direct-to-consumer networks often face regarding their compensation structures and business practices. While the company is appealing the decision and asserts its compliance, the incident highlights the inherent vulnerabilities of a model that can be disrupted by a single regulatory body.

For MyLife Wellness, this means its success is tied not only to product quality and market acceptance but also to the health and compliance of its distribution network. It must successfully recruit and retain a large, motivated base of sellers while carefully navigating a complex and often contentious regulatory environment, a challenge made more difficult by the parent company's past struggles.

Scrutinizing the 'Science-Backed' Promise

MyLife Wellness enters a market where terms like 'science-backed,' 'clean-ingredient,' and 'health optimization' are ubiquitous. The brand promises tangible results, from metabolic balance with its 'Amaze' supplement to cognitive support from its 'Drive' formula. Yet, these ambitious claims are accompanied by a standard but critical FDA disclaimer: 'These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.'

This disclaimer legally separates the products from regulated pharmaceuticals, placing the burden of proof for efficacy claims on the consumer's trust in the brand. For a new entrant like MyLife Wellness, building that trust is a monumental task. The DTC health and skincare markets are fiercely competitive, populated by established giants like Herbalife and Amway, digitally native darlings like Ritual and The Ordinary, and countless other brands all vying for the same consumer dollar.

Differentiation is key to survival. Investview appears to be banking on its internal manufacturing division, RENU Labs, to ensure product quality and control costs. However, in-house production does not guarantee market traction. MyLife Wellness must convince consumers its formulas are superior to the hundreds of alternatives available, a challenge compounded by the financial instability of its parent company, which could undermine long-term brand credibility.

The ultimate test for MyLife Wellness will be whether its products can deliver results compelling enough to generate organic demand beyond its initial direct-selling network. Without demonstrable effectiveness and a unique value proposition, the brand risks becoming just another name in a crowded field, unable to generate the revenue needed to rescue its parent company from its precarious financial state.